Senolytics hit the brain's ceiling — as thymus biology and human genetics step up
No new human RCT landed this cycle, and the sharpest human data point is a cautionary one: a peer-reviewed Phase 1 senolytic (D+Q) trial in mild Alzheimer's confirmed brain penetration and safety but moved none of the tau/amyloid biomarkers — a needed check on senolytics-for-brain enthusiasm. The mechanistic momentum is elsewhere: spatial mapping pins a senolytic-responsive senescent microglial state to aged white matter, and two immune-aging papers put the thymus back at the center of inflammaging. On the human-genetics front, a bioRxiv preprint reports a reduced-function cGAS variant enriched in long-lived families — an independent human-genetic convergence on the cGAS-STING axis this digest has tracked mechanistically. Read the preprint and the mouse work as hypothesis-strengthening, not settled evidence.
tau/amyloid biomarkers significantly improved by senolytic D+Q in a Phase 1 Alzheimer's trial (Neurotherapeutics 2025)
Where the human evidence is
Count by statusEvidence-stage map
Evidence stage × investigator promise (1–10)Senescence, senolytics & the aging brain
Spatial mapping localizes a senolytic-responsive senescent microglial state to aged white matter
Carver et al. used regional expression profiling, immunolabeling and GeoMx/CosMx spatial imaging to identify an aged-brain-exclusive microglial population concentrated in white matter that co-expresses disease-associated microglia (DAM) genes and a 'SenBrain' senescence signature, including galectin-3 (GAL3/Lgals3). Pharmacogenetic or pharmacological targeting of p16INK4a or BCL2 reduced GAL3+ DAM abundance and restored a more youthful microglial organization in the aged fimbria. A clean anatomical target linking senescence to brain aging — but the intervention data are murine.
Read the paperPhase 1 senolytic (dasatinib + quercetin) in mild Alzheimer's: safe, brain-penetrant, but biomarker-null
Evaluation of exploratory fluid biomarkers from the first open-label D+Q trial in early AD confirmed CNS penetration of dasatinib and a favorable safety profile, but found no statistically significant change across the tau- and amyloid-related biomarkers examined, and no significant shift in secondary cognitive or neuroimaging endpoints. Underpowered (n=5) and not designed for efficacy, so this refutes hype rather than the hypothesis — but it is a concrete caution against treating senolytics as a proven brain intervention. A Phase 2 RCT is underway.
Read the paperImmune aging & inflammaging — the thymus returns
Thymulin restrains age-associated myeloid inflammation and re-sensitizes tumors to immunotherapy
The thymus-derived hormone thymulin, which declines with age, is identified as a brake on cytokine-mediated myeloid inflammation. Restoring thymulin curbed inflammaging, enhanced antitumor T-cell immunity, improved tumor control and survival, and sensitized tumors to anti-PD-L1 therapy in an age-dependent manner. Positions a declining endocrine signal as a mechanistic link between immune aging and cancer-immunotherapy resistance — preclinical, mouse-stage.
Read the paperSingle-cell atlas of human thymus + blood maps how T-cell development fails with age
Profiling 387,762 cells from young and aged human thymus and peripheral blood shows aging reduces T-lineage potential in early thymic progenitors while increasing innate-lymphocyte lineage bias; the aged thymus is depleted of thymic epithelial cells and enriched for mature T cells with inflammatory profiles. A human reference for immunosenescence and a substrate for judging thymic-rejuvenation strategies — descriptive rather than interventional.
Read the paperHuman longevity genetics & neuro-longevity
Reduced-function cGAS variant enriched in multigenerational long-lived families
Sequencing of multigenerational long-lived families reports rare longevity-associated variants including a CGAS missense variant (rs200818241) that reduces protein stability and attenuates canonical cGAS-STING activation in a cell-type-specific manner. If it holds, this is human-genetic support for partial cGAS loss-of-function as protective — converging with the mechanistic cGAS-STING inflammaging story this digest has tracked, and sharpening the therapeutic-window question (damp inflammaging without losing antiviral/DNA-repair function). Preprint: treat as a lead, not established.
Read the paperKlotho gene-therapy proof-of-concept completes; data being prepared for publication (update)
Update to the klotho thread carried previously: the Minicircle plasmid klotho gene-therapy proof-of-concept reportedly completed in spring 2026 with results being prepared for publication, and a separate klotho+follistatin early-phase trial (adults 50–80) is recruiting. The peer-reviewed foundation remains the aged-macaque cognition result; human commercial translation is still an unverified early signal, not evidence of cognitive benefit in people.
Read the paper